Enlivex (ENLV) Research & Development (2013 - 2026)
Enlivex (ENLV) recorded Research & Development of $2.92 million in Q2 2026, up 36.5% from $2.14 million a year earlier.
Powered by 
Analysis
Enlivex (ENLV) Research & Development (2013 - 2026) Analysis & Trends
On a TTM basis, Enlivex's Research & Development came in at $9.58 million as of Jun 30, 2026, down 8.4% year-over-year; for FY2025, it was $9.2 million, down 13.4% from FY2024.
- Annual Research & Development has a five-year compound annual growth rate of 8.6% (FY2020 to FY2025).
- Across earlier years, Research & Development came in at $10.62 million in FY2024 (-44.1%), $19.01 million in FY2023 (+1.7%), $18.69 million in FY2022 (+45.1%) and $12.88 million in FY2021 (+111.6%).
- Quarterly Research & Development has ranged from $1.48 million in Q3 2025 to $5.7 million in Q4 2022 over the past five years.
- On a year-over-year basis, Research & Development rose in two of the last seven quarters, with an average decline of 12.1%.
- Peak year-over-year performance for Research & Development in the last five years was growth of 138.8% in Q3 2021, against a decline of 60.3% in Q2 2024 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,135.76 Bn | 1,104.34 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 619.07 Bn | 537.60 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 503.11 Bn | 476.22 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.23 Bn | 324.61 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.76 Bn | 262.75 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.14 Bn | 234.83 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.54 Bn | 192.94 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.65 Bn | 165.84 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.26 Bn | 116.90 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Enlivex | 610,806.00 | -48.37 Mn | - | 2.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.92 Mn |
| Dec 31, 2025 | 3.03 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Mar 31, 2025 | 2.55 Mn |
| Dec 31, 2024 | 3.42 Mn |
| Sep 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Mar 31, 2024 | 2.86 Mn |
| Dec 31, 2023 | 4.45 Mn |
| Sep 30, 2023 | 4.35 Mn |
| Jun 30, 2023 | 5.04 Mn |
| Mar 31, 2023 | 5.18 Mn |
| Dec 31, 2022 | 5.70 Mn |
| Sep 30, 2022 | 4.20 Mn |
| Jun 30, 2022 | 4.11 Mn |
| Mar 31, 2022 | 4.68 Mn |
| Dec 31, 2021 | 5.17 Mn |
| Sep 30, 2021 | 2.68 Mn |
| Jun 30, 2021 | 2.54 Mn |
API Access
Enlivex Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ENLV&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ENLV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ENLV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();